A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects

Inclusion Criteria: * Chronically infected with HCV genotype 1 * Treatment naive * HCV RNA viral load of ≥10\*5 IU/mL * BMI 18 to 35kg/m² Exclusion Criteria: * Women of childbearing potential (WOCBP) * Any significant acute or chronic medical illness which is not stable or is not controlled with medication and not consistent with HCV infection * HCV infected subjects who are treatment non-responder (defined as subject who received at least 12 weeks of SOC and continue to have a detectable HCV RNA level or subjects who did not attain a 2-log decline in HCV RNA levels at 12 weeks and stopped treatment * HCV infected subjects who are treatment intolerant (defined as subject who are unable to receive at least 12 weeks of SOC due to toxicities associated with interferon and/or ribavirin * HIV and/or HBV positive * Major surgery within 4 weeks of study drug administration and any gastrointestinal surgery that could impact the absorption of study drug